<DOC>
	<DOCNO>NCT00808262</DOCNO>
	<brief_summary>Evaluation safety immune response induce active immunization TNFa kinoid patient Crohn 's disease .</brief_summary>
	<brief_title>Safety Immunogenicity TNFa Kinoid Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must Active Crohn 's Disease , define Crohn 's Disease Activity Index ( CDAI ) score &gt; 220 â‰¤400 , active Crohn 's disease ileum and/or colon ( Other area may involve ileum and/or colon also involve ) base upon either endoscopic , histologic and/or radiographic evidence Patients active disease despite treatment 5ASAs sulfasalazine , corticosteroid ( prednisone , budesonide , ) , AZA 6MP cyclosporine MTX Tacrolimus , ; OR intolerant 5ASAs sulfasalazine ; intolerant antibiotic ; intolerant corticosteroid ( prednisone , budesonide , ) ; intolerant AZA 6MP cyclosporine MTX Tacrolimus Patients might previously respond prior antiTNF agent lose response OR might intolerant prior antiTNF agent Positive skin reaction challenge Candida antigens Written informed consent Prior history tuberculosis positive chest X ray positive purify protein derivative skin test positive interferon gamma TB assay Signs symptom clinically significant stricture bowel . Total parenteral nutrition elemental diet require treatment disease support short bowel syndrome Presence enteric stoma Imminent urgent surgery require infection , abscess , bleed cause relate Crohn 's Disease condition History malignancy . However , subject basal call carcinoma less 3 squamous cell carcinoma allow History asthma serious allergic condition ( include history seafood allergy ) Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose study drug History opportunistic infection exclude oral candidiasis steroid Enteric infection evidence positive stool C &amp; S , O &amp; P C. difficile obtain screen Any significant decompensated cardiac , neurologic , liver , pulmonary renal disease History lymphoproliferative disorder Clinically significant abnormal hematology value , determine investigator , hematocrit , hemoglobin , white blood cell count platelet Clinically significant abnormal blood chemistry value determine investigator Current significant drug alcohol abuse determine investigator Positive hepatitis C antibody positive hepatitis B surface antigen ( HbsAg ) HIV infection Surgery within previous 3 month ( minor cosmetic surgery minor dental procedure ) Participation clinical study ( include previous participation study ) within previous 4 month Had primary nonresponse prior antiTNF agent define investigator OR receive prior antiTNF agent within past 8 week prior study entry Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>anti-TNFa</keyword>
	<keyword>immunization</keyword>
	<keyword>kinoid</keyword>
	<keyword>crohn 's disease</keyword>
</DOC>